Latest

Early Opdivo OK gives BMS more time to erase Keytruda's lead

Early Opdivo OK gives BMS more time to erase Keytruda's lead

FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.

Gilead may be forced to discount hep. C pills

AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.

Five things for pharma marketers to know: Tuesday, December 23

Five things for pharma marketers to know: Tuesday, December 23

BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.

Walgreen to vote on merger with Alliance Boots

The 8,200-store chain would expand to 11,000 locations operating in 10 countries, if shareholders approve.

PBM deal on new hep.-C cocktail highlights drugmaker tolerance for discounts

PBM deal on new hep.-C cocktail highlights drugmaker tolerance for discounts

The agreement between AbbVie and Express Scripts is seen as a seismic shift in the joint development of cost-effective therapies, and gives the new regimen a slight edge on Gilead's popular remedies.

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

Five things for pharma marketers to know: Monday, December 22

Five things for pharma marketers to know: Monday, December 22

Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.

Five Big Shifts in Policy and Technology That Marketers Should Worry about in 2015

Five Big Shifts in Policy and Technology That Marketers Should Worry about in 2015

"The trouble is that the market is changing much faster than most marketers realize."

Five things for pharma marketers to know: Friday, December 19

Five things for pharma marketers to know: Friday, December 19

Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.

Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

Agency Spotlight



Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters